MedTrace Logo

HPV Vaccination in Special Risk Groups: 5 Year Follow-up

NCT01896986 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2017-06-15

Study results available
· View outcomes & findings →

Summary

In 2007-2009 the investigators conducted a study to determine the immunogenicity response to HPV vaccine in special risk patients known to be at increased risk of abnormal cervical cytology. The serological response to the vaccine was measured 1 month post the third and final dose (n=70) finding a robust response overall.

The aim of this follow-on study is to provide data on the long-term protection offered by the HPV vaccination. The persistence of antibody 5 years post immunisation is unknown and the impact on cervical cytology abnormalities in these special risk groups is important.

The study results will help inform national immunisation program recommendations re- booster HPV vaccine doses.

Conditions

  • PRD (Paediatric Rheumatological Disease)
  • IBD (Inflammatory Bowel Disease)

Sponsors & Collaborators

  • Monash Medical Centre

    collaborator OTHER

  • Murdoch Childrens Research Institute

    lead OTHER

Principal Investigators

  • Nigel Crawford, PhDMPHMBBS · Royal Childrens Hospital

Eligibility

Min Age
12 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01896986 on ClinicalTrials.gov